Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  2,935 results for ""Antirheumatic Agents""

Your Filters

Publication : annals of the rheumatic diseases
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial.

  • Authors : Lend K; Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands .; Division of Rheumatology, Department of Medicine, Karolinska Institute, Stockholm, Sweden.

Subjects: Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/genetics ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/immunology

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Nov 14; Vol. 83 (12), pp. 1657-1665. Date of Electronic Publication: 2024 Nov 14.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic)

Record details

Read More Add to Saved list
×
Academic Journal

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.

  • Authors : Feist E; Rheumatology and Clinical Immunology, HELIOS Fachklinik Vogelsang/Gommern, Vogelsang, Germany .; Experimental Rheumatology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.

Subjects: Methotrexate*/Methotrexate*/Methotrexate*/therapeutic use ; Methotrexate*/Methotrexate*/Methotrexate*/adverse effects ; Methotrexate*/Methotrexate*/Methotrexate*/administration & dosage

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Oct 21; Vol. 83 (11), pp. 1454-1464. Date of Electronic Publication: 2024 Oct 21.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic)

Record details

Read More Add to Saved list
×
Academic Journal

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years.

Subjects: Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/adverse effects ; Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/therapeutic use ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Aug 27; Vol. 83 (9), pp. 1110-1117. Date of Electronic Publication: 2024 Aug 27.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic)

Record details

Read More Add to Saved list
×
Academic Journal

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.

Subjects: Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy ; Janus Kinase Inhibitors*/Janus Kinase Inhibitors*/Janus Kinase Inhibitors*/therapeutic use ; Janus Kinase Inhibitors*/Janus Kinase Inhibitors*/Janus Kinase Inhibitors*/adverse effects

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Aug 27; Vol. 83 (9), pp. 1189-1199. Date of Electronic Publication: 2024 Aug 27.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic)

Record details

Read More Add to Saved list
×
Academic Journal

Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.

Subjects: Rheumatic Diseases*/Rheumatic Diseases*/Rheumatic Diseases*/drug therapy ; COVID-19 Vaccines* ; COVID-19*/COVID-19*/COVID-19*/prevention & control

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Oct 21; Vol. 83 (11), pp. 1584-1595. Date of Electronic Publication: 2024 Oct 21.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic)

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease.

  • Authors : Yoshimura Y; Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan.; Yamanouchi M

Subjects: Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/complications ; Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/therapeutic use

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Sep 30; Vol. 83 (10), pp. 1278-1287. Date of Electronic Publication: 2024 Sep 30.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic)

Record details

Read More Add to Saved list
×
Academic Journal

Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set.

  • Authors : Lage-Hansen PR; Department of Rheumatology, Esbjerg and Grindsted Hospital, Esbjerg, Denmark .; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.

Subjects: Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/therapeutic use ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy ; Outcome Assessment, Health Care*/Outcome Assessment, Health Care*/Outcome Assessment, Health Care*/methods

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Sep 30; Vol. 83 (10), pp. 1288-1294. Date of Electronic Publication: 2024 Sep 30.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic)

Record details

Read More Add to Saved list
×
Academic Journal

Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain.

  • Authors : Baerwald C; Zentrum für Seltene Erkrankungen, University Hospital Leipzig, Leipzig, Germany .; Stemmler E

Subjects: Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/complications ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy ; Pain Measurement*/Pain Measurement*/Pain Measurement*/methods

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Sep 30; Vol. 83 (10), pp. 1381-1388. Date of Electronic Publication: 2024 Sep 30.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic)

Record details

Read More Add to Saved list
×
Editorial & Opinion

No sign of elevated cardiovascular risk in patients with seropositive rheumatoid arthritis who remain on stable antirheumatic therapy: results from the nationwide Norwegian Cardio-Rheuma Register.

  • Authors : Ikdahl E; REMEDY Center for treatment of Rheumatic and Musculoskeletal Diseases, Diakonhjemmet Hospital, Oslo, Norway .; Semb AG

Subjects: Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/complications ; Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/therapeutic use

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Aug 27; Vol. 83 (9), pp. 1226-1227. Date of Electronic Publication: 2024 Aug 27.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic)

Record details

Read More Add to Saved list
×
Academic Journal

bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease.

  • Authors : Kvacskay P; Department of Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; Hegenbart U

Subjects: Kidney Failure, Chronic*/Kidney Failure, Chronic*/Kidney Failure, Chronic*/etiology ; Kidney Failure, Chronic*/Kidney Failure, Chronic*/Kidney Failure, Chronic*/complications ; Kidney Failure, Chronic*/Kidney Failure, Chronic*/Kidney Failure, Chronic*/prevention & control AA amyloidosis

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Aug 27; Vol. 83 (9), pp. 1200-1207. Date of Electronic Publication: 2024 Aug 27.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic)

Record details

Read More Add to Saved list
×
  • 1-10 of  2,935 results for ""Antirheumatic Agents""